Rani's RT-114 Oral Capsule Shows Strong Bioavailability In Phase 1a Study; Phase 1b Underway

Rani Therapeutics reported positive initial Phase 1a data for RT-114, an orally administered RaniPill Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist being developed with ProGen. While still early-stage, the update is a supportive catalyst for the program’s clinical prospects.

Analysis

Rani Therapeutics reported positive initial Phase 1a data for RT-114, an orally administered RaniPill Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist being developed with ProGen. While still early-stage, the update is a supportive catalyst for the program’s clinical prospects.